Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EBS 
Emergent Biosolutions Inc (EBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: EBS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.59% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 447.62M USD | Price to earnings Ratio 3.2 | 1Y Target Price 13.5 |
Price to earnings Ratio 3.2 | 1Y Target Price 13.5 | ||
Volume (30-day avg) 3 | Beta 1.98 | 52 Weeks Range 4.02 - 12.73 | Updated Date 08/28/2025 |
52 Weeks Range 4.02 - 12.73 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.1 | Actual 0.16 |
Profitability
Profit Margin 16.38% | Operating Margin (TTM) 0.35% |
Management Effectiveness
Return on Assets (TTM) 5.03% | Return on Equity (TTM) 30.24% |
Valuation
Trailing PE 3.2 | Forward PE 66.23 | Enterprise Value 858785940 | Price to Sales(TTM) 0.53 |
Enterprise Value 858785940 | Price to Sales(TTM) 0.53 | ||
Enterprise Value to Revenue 1.06 | Enterprise Value to EBITDA 2.49 | Shares Outstanding 53351100 | Shares Floating 48259270 |
Shares Outstanding 53351100 | Shares Floating 48259270 | ||
Percent Insiders 2.84 | Percent Institutions 70.04 |
Upturn AI SWOT
Emergent Biosolutions Inc
Company Overview
History and Background
Emergent BioSolutions Inc. was founded in 1998 as BioPort Corporation to acquire and modernize a Michigan anthrax vaccine facility. It later changed its name to Emergent BioSolutions in 2004, expanding its focus to broader biodefense solutions and evolving into a global specialty biopharmaceutical company.
Core Business Areas
- Anthrax Vaccines: Development, manufacturing, and sales of anthrax vaccines like BioThrax and AV7909 (NuThrax).
- Narcan Nasal Spray: Sales of Narcan nasal spray, an emergency treatment for opioid overdose.
- Contract Development and Manufacturing (CDMO): Provides contract development and manufacturing services to other pharmaceutical and biotechnology companies.
Leadership and Structure
The leadership team is headed by Joseph C. Papa, President and CEO. The organizational structure includes various departments for research and development, manufacturing, sales and marketing, and administration. They have a board of directors overseeing the company's strategy and operations.
Top Products and Market Share
Key Offerings
- AV7909: An anthrax vaccine with potentially improved safety and immunogenicity compared to BioThrax. Competitor is generally academic research.
- BioThrax: Anthrax vaccine used by the U.S. government for biodefense. It has been a reliable revenue generator. Market share difficult to determine precisely, as it's mainly government contracts. Competitor is generally academic research.
- Narcan Nasal Spray: An over-the-counter naloxone nasal spray for the emergency treatment of opioid overdose. Competitors include Teva Pharmaceutical Industries (TEVA) and generic naloxone.
- Vivotif: Typhoid fever vaccine, competitor is PaxVax.
Market Dynamics
Industry Overview
The biodefense market is driven by government funding and the need to protect against biological threats. The opioid overdose treatment market is driven by the ongoing opioid crisis. The CDMO market is growing due to increased outsourcing by pharmaceutical companies.
Positioning
Emergent BioSolutions is positioned as a key player in the biodefense market, holding significant contracts with the U.S. government. In the opioid overdose treatment market, Narcan is a leading brand. They are a mid-sized player in the CDMO market.
Total Addressable Market (TAM)
The TAM for biodefense is projected to reach billions of dollars annually. The TAM for opioid overdose reversal is also significant, driven by the opioid epidemic. Emergent is addressing a portion of the TAM for each, but is primarily positioned within the Anthrax Vaccine Market.
Upturn SWOT Analysis
Strengths
- Strong government relationships
- Established product portfolio in biodefense
- Specialized manufacturing capabilities
Weaknesses
- High dependence on government contracts
- Past manufacturing issues affecting reputation
- Limited product diversification beyond biodefense
Opportunities
- Expanding into new biodefense areas
- Acquiring complementary businesses
- Increasing sales of Narcan
Threats
- Competition from other biodefense companies
- Changes in government funding priorities
- Generic competition for Narcan
Competitors and Market Share
Key Competitors
- SIGA
- CBRX
- HHS
Competitive Landscape
Emergent BioSolutions' advantages include established relationships with government agencies and a specialized manufacturing infrastructure. Disadvantages include dependence on government contracts and the need for broader product diversification. SIGA Technologies is a strong competitor in the biodefense space.
Major Acquisitions
Adapt Pharma
- Year: 2018
- Acquisition Price (USD millions): 735
- Strategic Rationale: Acquisition of Adapt Pharma to acquire Narcan Nasal Spray and expand its presence in the opioid overdose treatment market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by government contracts and acquisitions.
Future Projections: Future growth is dependent on securing new contracts and expanding the product portfolio. Analyst estimates vary.
Recent Initiatives: Recent initiatives include focusing on core competencies and seeking strategic partnerships. Potential expansion into pandemic response.
Summary
Emergent BioSolutions is a key player in the biodefense industry, particularly with anthrax vaccines and Narcan nasal spray. Their reliance on government contracts presents both opportunities and risks. While established in its niche, expanding its product portfolio beyond biodefense is vital for future growth. Recent manufacturing issues have hurt the company, and they need to ensure operational excellence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Emergent Biosolutions Inc
Exchange NYSE | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2006-11-15 | CEO, President & Director Mr. Joseph C. Papa Jr., M.B.A., R.Ph. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 900 | |
Full time employees 900 | |||
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.